公开(公告)号：KR1020120120074A

公开(公告)日：2012-11-01

申请号：KR1020120041597

申请日：2012-04-20

Applicant: 가톨릭대학교 산학협력단

Inventor： 이문용 ,  차정호 ,  신유진

IPC: A61K38/17 ,  G01N33/68 ,  C07K14/47 ,  A61P25/00

CPC classification number: A61K38/1703 ,  C07K14/4702 ,  G01N33/68

Abstract: PURPOSE: A composition for a bio marker for determining neuronal cell debris using osteopontin is provided to remove neuronal cell debris and degenerating neurite. CONSTITUTION: A composition for a bio marker for determining neuronal cell apoptosis contains osteopontin for providing information for diagnosing nervous system diseases. The neuronal cells are CA1(cornu ammonis 1) or striatum of hippocampus. The nervous system diseases are ischemic brain injury, traumatic neural injury, stroke, CNS or PANA demyelination diseases, neuropathy, or neurodegenerative diseases. The composition is used for removing debris caused by neuronal cell apoptosis and degenerating neurite. A composition for treating nervous system diseases contains the osteopontin. The composition also contains cells transformed with a recombinant expression vector or a vector containing osteopontin gene.

Abstract translation: 目的：提供用于使用骨桥蛋白测定神经元细胞碎片的生物标志物的组合物，以去除神经元细胞碎片和退化的神经突。 构成：用于确定神经元细胞凋亡的生物标记物的组合物含有骨桥蛋白用于提供用于诊断神经系统疾病的信息。 神经元细胞为CA1（Cornu ammonis 1）或海马纹状体。 神经系统疾病是缺血性脑损伤，创伤神经损伤，中风，CNS或PANA脱髓鞘疾病，神经病变或神经变性疾病。 该组合物用于去除由神经元细胞凋亡和退化神经突引起的碎屑。 用于治疗神经系统疾病的组合物含有骨桥蛋白。 该组合物还含有用重组表达载体或含有骨桥蛋白基因的载体转化的细胞。

公开(公告)号：KR1020110133133A

公开(公告)日：2011-12-12

申请号：KR1020100052692

申请日：2010-06-04

Applicant: 가톨릭대학교 산학협력단

Inventor： 이문용 ,  차정호 ,  최정선 ,  신유진

IPC: C12Q1/68 ,  G01N33/68 ,  C12N15/12 ,  C07K14/71

CPC classification number: C12Q1/6883 ,  C07K14/71 ,  C12Q1/6837 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/6893

Abstract: PURPOSE: A VEGFR-3 gene as a marker for stroke diagnosis is provided to early and accurately diagnose and predict stroke. CONSTITUTION: A marker for stroke diagnosis contains VEGFR-3(vascular endothelial growth factor receptor-3) gene or VEGFR-3 protein encoded by the gene. The VEGFR-3 gene has a base sequence of sequence number 1. A composition for stroke diagnosis contains a material for measuring VEGFR-3 gene or protein level. A method for stroke diagnosis comprises: a step of measuring the amount of VEGFR-3 gene or protein existing in a biological sample; and a step of comparing the VEGFR-3 gene expression level or protein amount from a control group.

Abstract translation: 目的：提供作为卒中诊断标志物的VEGFR-3基因，以早期准确诊断和预测中风。 构成：卒中诊断标记物含有VEGFR-3（血管内皮生长因子受体-3）基因或由该基因编码的VEGFR-3蛋白。 VEGFR-3基因具有序列号1的碱基序列。用于中风诊断的组合物含有用于测量VEGFR-3基因或蛋白质水平的材料。 一种中风诊断方法包括：测量存在于生物样品中的VEGFR-3基因或蛋白质的量的步骤; 以及比较来自对照组的VEGFR-3基因表达水平或蛋白质量的步骤。

公开(公告)号：KR101449100B1

公开(公告)日：2014-10-13

申请号：KR1020120041597

申请日：2012-04-20

Applicant: 가톨릭대학교 산학협력단

Inventor： 이문용 ,  차정호 ,  신유진

IPC: A61K38/17 ,  G01N33/68 ,  C07K14/47 ,  A61P25/00

Abstract: 본 발명은 오스테오폰틴(osteopontin)의 발현이 신경세포의 사멸에 대한 지표인 사실 및 오스테오폰틴이 신경세포사에 의한 신경세포 데브리스(debris) 및 퇴행중 신경돌기를 타겟팅하여 이들을 제거하는데 사용되는 사실과 이의 구체적인 작용기작에 기초하는, 오스테오폰틴의 신규한 용도에 관한 것이다.

公开(公告)号：KR1020120004097A

公开(公告)日：2012-01-12

申请号：KR1020100064762

申请日：2010-07-06

Applicant: 가톨릭대학교 산학협력단

Inventor： 이문용 ,  차정호 ,  신유진

IPC: A61K38/18 ,  A61K38/17 ,  A61K31/713 ,  A61P9/10

CPC classification number: A61K38/18 ,  A61K48/00 ,  G01N33/5044 ,  G01N2500/10 ,  Y10S514/893 ,  Y10S514/912

Abstract: PURPOSE: A composition containing VEGFR-3 for preventing or treating ischemic diseases is provided to promote infiltrating exogenous macrophage activity and to treat ischemic damage. CONSTITUTION: A composition for preventing or treating ischemic diseases contains VEGFR-3(vascular endothelial growth factor receptor-3) or nucleic acids encoding the protein. The VEGFR-3 protein has an amino acid of sequence number 1. The nucleic acid has a polynucleotide of sequence number 2. A method for screening a material for preventing or treating ischemic diseases comprises: a step of contacting with a sample to be analyzed to cells containing VEGFR-3 protein or the gene encoding the protein; a step of measuring VEGFR-3 protein level, activity, or gene expression level; and a step of determining the sample as a material for preventing or treating ischemic diseases.

Abstract translation: 目的：提供含有用于预防或治疗缺血性疾病的VEGFR-3的组合物，以促进浸润的外源性巨噬细胞活性和治疗缺血性损伤。 构成：用于预防或治疗缺血性疾病的组合物含有VEGFR-3（血管内皮生长因子受体-3）或编码该蛋白质的核酸。 VEGFR-3蛋白具有序列号1的氨基酸。核酸具有序列号2的多核苷酸。用于筛选预防或治疗缺血性疾病的材料的方法包括：将待分析的样品与 含有VEGFR-3蛋白的细胞或编码蛋白质的基因; 测量VEGFR-3蛋白水平，活性或基因表达水平的步骤; 以及将样品确定为用于预防或治疗缺血性疾病的材料的步骤。